New retinal navigation system gains approval

Article

The NAVILAS laser system, as reported on in the OTE Digest back in May this year ( What is Retinal Navigation? ) has been given FDA approval.

The NAVILAS laser system, as reported on in the OTE Digest back in May this year (What is Retinal Navigation? ) has been given FDA approval.

The new navigated laser system incorporates advanced imaging with retinal laser therapy in a planned and controlled way using image registration in one device with integrated workflow to improve the safety, accuracy, speed, comfort and transparency of retina laser photocoagulation which is the current standard in the treatment of many retinal disorders including Diabetic Retinopathy and Diabetic Macular Edema (DME).

NAVILAS is designed to allow doctors to move beyond conventional slit lamp based photocoagulation that provides only a partial slit image of the retina. The system produces a live image of the fundus in true color, IR and red-free as well as fluorescien angiography (FA) with 50 degree field of view on a monitor - panable across the fundus. The patented imaging technology is capable of real-time imaging of the retina in color - both mydratic and non-mydratic - while including a treatment laser to treat the retina.

“In trials, initial accuracy results with NAVILAS indicate a microaneurysm hit rate of 92% as evidenced by post treatment color overlay photographs,” reported Dr William Freeman, Professor and Director of the Jacobs Retina Centreat the UCSD Shiley Eye Centre in California, during his presentation at Retina Subspecialty Day of the AAO 2009 in San Francisco.

With NAVILAS, doctors have freedom of neck movement and are able to adjust their height and proximity to the patient for maximum ergonomic benefits. "The neck and back strain of slit lamp examination will be greatly reduced," said Dr. Michael Ober, Retina Consultants of Michigan, Southfield Michigan.>

Subscribe to the Ophthalmology Times Digest Europe

www.od-os.com

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.